Resource Central is a product of the Pediatric Pandemic Network.

Nirsevimab Library

This is a collection of current resources related to Nirsevimab.

Nirsevimab to Reduce Infant Morbidity From Respiratory Syncytial Virus
2024 · Dalhousie University, · University of British Columbia
This article describes how nirsevimab, a long-acting monoclonal antibody, helps prevent respiratory syncytial virus (RSV) infections in infants. RSV is a common virus that can …
Cost-Effectiveness Analysis of Nirsevimab and RSVpreF Vaccine Prevention Strategies for Respiratory Syncytial Virus Disease in Infants: A Canadian Immunisation Research Network (CIRN) Study
2023 · York University, · Yale University, · Dalhousie University
This study looks at the cost-effectiveness of two strategies to prevent RSV disease in infants in Canada. It describes using nirsevimab, a long-acting antibody, for …
Cost-Effectiveness Analysis of Nirsevimab and Maternal Rsvpref Vaccine Strategies for Prevention of Respiratory Syncytial Virus Disease Among Infants in Canada: A Simulation Study
2023 · Yale University, · York University, · Dalhousie University
This study in Canada assessed cost-effectiveness of nirsevimab and RSVpreF for preventing RSV in infants. Modeling different interventions showed immunizing the birth cohort with nirsevimab …

Looking for different way to find resources?

Our chatbot aRCie can help with a more personalized search. Click below to try our new chatbot.

Try aRCie